| Literature DB >> 25340556 |
Benjamin R Deist1, Michael A Rausch2, Maria Teresa Fernandez-Luna3, Michael J Adang4, Bryony C Bonning5.
Abstract
Insect-specific toxins derived from Bacillus thuringiensis (Bt) provide a valuable resource for pest suppression. Here we review the different strategies that have been employed to enhance toxicity against specific target species including those that have evolved resistance to Bt, or to modify the host range of Bt crystal (Cry) and cytolytic (Cyt) toxins. These strategies include toxin truncation, modification of protease cleavage sites, domain swapping, site-directed mutagenesis, peptide addition, and phage display screens for mutated toxins with enhanced activity. Toxin optimization provides a useful approach to extend the utility of these proteins for suppression of pests that exhibit low susceptibility to native Bt toxins, and to overcome field resistance.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25340556 PMCID: PMC4210883 DOI: 10.3390/toxins6103005
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Schematic representation of the major steps involved in Cry toxicity and sites for modification to increase efficacy and/or broaden toxicity. Some of the insect species successfully targeted by modified toxins are shown at right [16,17,18].
Figure 2Models for addition mutants of Cyt2Aa (CGALn) with the pea aphid gut binding peptide GBP3.1 (GBP) incorporated into various loops (Ln) and exposed on the surface of Cyt2Aa. Homology based models were developed by LOMETS. Source: [85]. Of these modified toxins, the binding and toxicity of CGAL1, CGAL3 and CGAL4 in the pea aphid were both increased. Engineering to produce CGAL2, CGAL5 and CGAL7 resulted in loss of Cyt2Aa toxicity to mosquito larvae [81].
Selected modifications made to Bt toxins for improved efficacy.
| Type of Modification | Bt Toxin | Insect Targeted | Reference |
|---|---|---|---|
| Truncation and selection of mutant toxins from phage display library based on binding affinity | Cry1Ia | [ | |
| Truncated Helix α-1 of Domain I | Cry1A | [ | |
| Truncated Helix α-1 of Domain I | Cry1A | [ | |
| Truncated | Cry1 HD-1 Dipel | [ | |
| Truncated | Cry1 HD-1 Dipel | [ | |
| Truncated | Cry1Ba | [ | |
| Truncated | Cry1C | [ | |
| Truncated | Cry2A | [ | |
| Truncated | Cry4A | [ | |
| Truncated | Cry11 | [ | |
| Truncated | Cry11A | [ | |
| Truncated | Cry15A | [ | |
| Truncated | Cry1A | [ | |
| Chymotrypsin/cathepsin G cleavage site in domain I | Cry3Aa | [ | |
| Mutation of potential trypsin and chymotrypsin sites to resist degradation | Cry1Aa | [ | |
| Domain III swap with Cry1Ab | mCry3Aa | [ | |
| Domain III swap with Cry1C | Cry1Ab | [ | |
| Domain III swap with Cry1Ca | Cry1Ab | [ | |
| Domain III swap with Cry1Ac | Cry1Ca | [ | |
| Domain II and domain III swapping between Cry1Ia and Cry1Ba | Cry1Ia | [ | |
| Substitutions in loop 1, loop 2, and loop 3 of domain II | Cry4Ba | [ | |
| Substitutions in loop 1 and loop 2 of domain II | Cry19Aa | [ | |
| Subsitutions/deletions in domain II | Cry1Ab | [ | |
| Substitutions/deletions in loop 1 and loop 2 of domain II | Cry1Aa | [ | |
| Substitutions/deletions in loop 1 of domain II | Cry3A | [ | |
| Incorporation of binding peptide into various loops | Cyt2Aa | [ | |
| Cry1Ac | [ | ||
| Replacement of domain III with Allium sativum lectin | Cry1Ac | [ | |
| Cry3Aa | [ | ||
| Selection of mutant toxins from phage display library based on binding affinity | Cry1Aa | [ | |
| Selection of mutant toxins from phage display library based on binding affinity | Cry8Ka | [ | |
| Selection of mutant toxins from phage display library based on binding affinity | Cry1Aa | [ | |